CN110075216A - It is a kind of with the food compositions and preparation method thereof, preparation and the application that assist reducing blood lipid, hepatoprotective effect of losing weight - Google Patents
It is a kind of with the food compositions and preparation method thereof, preparation and the application that assist reducing blood lipid, hepatoprotective effect of losing weight Download PDFInfo
- Publication number
- CN110075216A CN110075216A CN201910419308.2A CN201910419308A CN110075216A CN 110075216 A CN110075216 A CN 110075216A CN 201910419308 A CN201910419308 A CN 201910419308A CN 110075216 A CN110075216 A CN 110075216A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- blood lipid
- preparation
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008280 blood Substances 0.000 title claims abstract description 67
- 210000004369 blood Anatomy 0.000 title claims abstract description 66
- 235000013305 food Nutrition 0.000 title claims abstract description 54
- 150000002632 lipids Chemical class 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000002443 hepatoprotective effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 27
- 210000004185 liver Anatomy 0.000 claims abstract description 43
- 239000000843 powder Substances 0.000 claims abstract description 31
- 230000000968 intestinal effect Effects 0.000 claims abstract description 30
- 244000269722 Thea sinensis Species 0.000 claims abstract description 27
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 26
- 235000009569 green tea Nutrition 0.000 claims abstract description 26
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 25
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 25
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 25
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 25
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 25
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 25
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 25
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 25
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 25
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 25
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 25
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 25
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 24
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 24
- 240000000249 Morus alba Species 0.000 claims abstract description 21
- 244000197580 Poria cocos Species 0.000 claims abstract description 21
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 21
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 20
- 229920002752 Konjac Polymers 0.000 claims abstract description 20
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 20
- 244000189799 Asimina triloba Species 0.000 claims abstract description 19
- 235000006264 Asimina triloba Nutrition 0.000 claims abstract description 19
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 19
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 claims abstract description 17
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 14
- -1 oral solution Substances 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000002710 Ilex cornuta Nutrition 0.000 claims 1
- 241001310146 Ilex cornuta Species 0.000 claims 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 18
- 239000002994 raw material Substances 0.000 abstract description 13
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 abstract description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 abstract description 9
- 241000192125 Firmicutes Species 0.000 abstract description 9
- 230000037396 body weight Effects 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 8
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 241000605059 Bacteroidetes Species 0.000 abstract description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 3
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 3
- 230000001976 improved effect Effects 0.000 abstract description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 3
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 39
- 241001092040 Crataegus Species 0.000 description 22
- 241000229143 Hippophae Species 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 15
- 150000003626 triacylglycerols Chemical class 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 238000007405 data analysis Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 239000002075 main ingredient Substances 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 235000008216 herbs Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000721047 Danaus plexippus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 108700022737 rat Fat1 Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 241000192142 Proteobacteria Species 0.000 description 4
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 4
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 244000144993 groups of animals Species 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000013238 high-fat diet model Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 240000007087 Apium graveolens Species 0.000 description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 3
- 235000010591 Appio Nutrition 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 101000800134 Rattus norvegicus Thyroglobulin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001593 brown adipocyte Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004155 insulin signaling pathway Effects 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 101710142885 Arginine N-succinyltransferase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 240000000425 Chaenomeles speciosa Species 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 235000008440 Crataegus cuneata Nutrition 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 240000006859 Jasminum officinale Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 101710105284 Sialin Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004897 positive regulation of fat cell differentiation Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a kind of with the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight, and is made of by weight following raw material: 20~25 parts of hawthorn, 20~25 parts of lotus leaf, 10~16 parts of pueraria lobata, 10~18 parts of green tea, 4~6 parts of fructus lycii, 4~8 parts of Poria cocos, 2~4 parts of sea-buckthorn, 1~3 part of celery powder, 1~3 part of mulberry leaf, 1~2 part of konjaku powder, 1~3 part of pawpaw, 1~2 part of rhizoma polygonati.Food compositions prepared by the present invention can significantly reduce hyperlipidemia model rat body weight, rouge/body ratio, food utilization and blood triglyceride, total cholesterol and low-density lipoprotein cholesterol level in each component dosage range；Also hyperlipidemia model rat liver index and glutamic-pyruvic transaminase, alkaline phosphatase levels can be reduced；And it is remarkably improved Bacteroidetes relative abundance, and reduce Firmicutes relative abundance, has effects that explicitly to assist reducing blood lipid, weight-reducing, liver protection and improves intestinal flora.
Description
Technical field
The invention belongs to health food and pharmaceutical technology fields, and in particular to one kind has auxiliary reducing blood lipid, weight-reducing liver protection
And improve the functional food composite of intestinal flora effect.
Background technique
People's living standard increasingly improves and the change of living habit, and diet nutritional enriches therewith, intake it is high-fat, high
Cholesterol and high sugar food are more and more, more and more so as to cause hyperlipidemia and obese people, and increasingly become younger.
Hyperlipidemia (Hyperlipidemia, HLP) is a kind of disease that internal disorders of lipid metabolism causes blood lipid level to increase, and is referred to
Cholesterol (TC), triglycerides (TG), very low density lipoprotein (VLDL), low-density lipoprotein in blood plasma caused by a variety of causes
(LDL) a kind of whole body Anomalous lipid metablism disease that raising and (or) high-density lipoprotein (HDL) reduce.According to statistics, China's blood
Rouge abnormality prevalence rate 18.6%, up to 30%, part age group has dyslipidemia illness rate some areas hyperlipidemia illness rate
Up to 40%.Now suffer from number 1.6 hundred million, is greater than 35 years old hypertension complicated with hyperlipemia up to 37,000,000 people.Obesity refers to body fat group
Knit a kind of pathological state that excess accumulation causes body normal physiological function to damage in various degree.Its cause of disease is complicated, it is believed that with ring
The factors such as border, heredity, physiology, metabolism, behavior and psychology are related.Obesity is cardiovascular disease, diabetes, chronic kidney disease, more
The risk factors of kind cancer and a series of skeletal muscles disease, this point is by epidemiological studies as a result, it was confirmed that but complete
Ball is overweight and fat people is still more and more.Hyperlipidemia and the fat Major risk factors for having become cardiovascular and cerebrovascular disease it
One, it is easy to induce a variety of cardiovascular and cerebrovascular diseases such as atherosclerosis, coronary atherosclerotic heart disease, cerebral apoplexy, is
The current highest disease of the death rate in the world.Investigation of clinical epidemiology the result shows that, whole world cardiovascular and cerebrovascular disease is averaged
Illness rate is 10~30%, and has the tendency that increasing year by year.
In recent years, research shows that intestinal flora and hyperlipidemia have with obesity is closely connected.It is micro- to account for body for intestinal flora
The 78.67% of biological total amount is the most important component part of body microecosystem.Intestinal flora take part in host metabolism,
The processes such as immune, physiology, biochemistry, pharmacology, metabolic activity influence the absorption of host's nutriment and the balance of energy.Enteron aisle is just
Normal flora has the function of adjusting blood lipid and adjusting weight, Bacillus acidi lactici, Bifidobacterium, enterococcus in intestinal flora etc. and gallbladder
Steroid metabolism has direct relation.Hyperlipidemia and obesity can make the environment that microorganism depends on for existence in enteron aisle change, and manage
Change the metabolism of normal intestinal floras such as changes influence Bifidobacterium, Bacillus acidi lactici and the enterococcus of property and the structure of matter and
Growth and breeding significantly reduces its quantity, and enterobacteria quantity is then opposite to be increased, to flora imbalance occur.In addition, to brood
The discovery of the study on intestinal flora of fat or thin mouse and girth of a garment volunteer, heavy wall flora in the enteron aisle of obese individuals (Firmicutes,
" fat bacterium ") increase with the ratio of bacteroid group (Bacteriodetes, " thin bacterium "), the diversity of flora is reduced, both floras
Quantity and diet and body fat content it is closely related.And specific food is supplemented, beneficial bacterium can increased to a certain degree, inhibiting harmful
Bacterium adjusts metabolism so as to improve the intestinal flora of imbalance, reduces blood lipid and mitigates fat.
Common fat-reducing medicament clinical at present has Hydroxymethylglutaryl list acyl coenzyme A reductase inhibitor (Statins), benzene oxygen
Aromatic acids, niacin class, clofibrate, cholic acid chelating resin class, selective cholesterol absorption inhibitor (clothing Ezetimibe) etc..This
Though a little drugs play the role of preferably reducing triglycerides and cholesterol, majority can cause abdominal distension, nausea, diarrhea etc. bad anti-
It answers, some drugs can also cause blood glucose rise and hepatic disorder etc..Currently, operation, movement and drug are treatment obesity
Main method, but there is complication more in these treatment methods and means.And under the guidance of theory of traditional Chinese medical science, integration of drinking and medicinal herbs Chinese medicine
It is widely used to the treatment of hyperlipidemia and obesity, by multipath, multiple target point regulating lipid metabolism, lipid-loweringing loss of weight, together
When can promote Liver Lipid Metabolism, reduce fat deposition, protect liver；In addition, Chinese medicine by oral administration after, effective component enters stomach
It interacts after enteron aisle with intestinal flora and improves intestinal flora.Therefore, develop it is a kind of with good effect, have no toxic side effect it is more
Functional food composition has wide development and application prospect.
Summary of the invention
The object of the present invention is to provide a kind of auxiliary reducing blood lipid being made of the Chinese medicine of integration of drinking and medicinal herbs, weight-reducing liver protection
And multifunctional food composition for improving intestinal flora and preparation method thereof, preparation and application, preparation process is simple, curative effect
Good, safety is without side-effects.
Above-mentioned purpose of the invention is achieved by the following technical programs: one kind having auxiliary reducing blood lipid, weight-reducing
The food compositions of hepatoprotective effect are made of by weight following components: 20~25 parts of hawthorn, 20~25 parts of lotus leaf, pueraria lobata 10
~16 parts, 10~18 parts of green tea, 4~6 parts of fructus lycii, 4~8 parts of Poria cocos, 2~4 parts of sea-buckthorn, 1~3 part of celery powder, mulberry leaf 1~3
Part, 1~2 part of konjaku powder, 1~3 part of pawpaw, 1~2 part of rhizoma polygonati.
Wherein, the mass parts of each component are preferably as follows:
(1) prescription 1: 20 parts of hawthorn, 20 parts of lotus leaf, 10 parts of pueraria lobata, 10 parts of green tea, 5 parts of fructus lycii, 5 parts of Poria cocos, sea-buckthorn 2
Part, 2 parts of celery powder, 3 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati.
(2) prescription 2: 25 parts of hawthorn, 25 parts of lotus leaf, 15 parts of pueraria lobata, 18 parts of green tea, 6 parts of fructus lycii, 4 parts of Poria cocos, sea-buckthorn 4
Part, 1 part of celery powder, 2 parts of mulberry leaf, 1 part of konjaku powder, 3 parts of pawpaw, 2 parts of rhizoma polygonati.
(3) prescription 3: 24 parts of hawthorn, 20 parts of lotus leaf, 12 parts of pueraria lobata, 12 parts of green tea, 4 parts of fructus lycii, 8 parts of Poria cocos, sea-buckthorn 2
Part, 2 parts of celery powder, 1 part of mulberry leaf, 2 parts of konjaku powder, 2 parts of pawpaw, 1 part of rhizoma polygonati.
A kind of preparation method with the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight, comprising the following steps:
(1) 20~25 parts of hawthorn, 20~25 parts of lotus leaf, 10~16 parts of pueraria lobata, 10~18 parts of green tea, fructus lycii are weighed respectively by weight
Sub 4~6 parts, 4~8 parts of Poria cocos, 2~4 parts of sea-buckthorn, 1~3 part of celery powder, 1~3 part of mulberry leaf, 1~2 part of konjaku powder, pawpaw 1
~3 parts, 1~2 part of rhizoma polygonati, clean, purify, dry, crush, and cross 120 meshes, obtain powder；
(2) after mixing above-mentioned powder, above-mentioned 20% mannitol of powder total weight is added, is uniformly mixed, then pelletize,
It is dry, obtain hybrid particles；
(3) magnesium stearate of its total weight 0.5% is added in hybrid particles, is uniformly mixed, required dosage form is then made.
The food compositions with auxiliary reducing blood lipid, hepatoprotective effect of losing weight assist reducing blood lipid, weight-reducing, guarantor as preparation
Protect liver is dirty, improves purposes in the health food of intestinal flora.
The food compositions with auxiliary reducing blood lipid, hepatoprotective effect of losing weight assist reducing blood lipid, weight-reducing, guarantor as preparation
Protect liver is dirty, improves the purposes of the drug of intestinal flora.
The food compositions with auxiliary reducing blood lipid, hepatoprotective effect of losing weight of the invention can according to need the auxiliary material system of addition
For at any suitable oral preparation.
The peroral dosage form is granule, tablet, capsule, bagged instant preparation, effervescent agent, powder, oral solution, pill etc., excellent
It is selected as granule, tablet, capsule and bagged instant preparation.
The auxiliary material is general pharmaceutically acceptable auxiliary material.
Each component effect of the present invention is as follows:
(1) hawthorn is rosaceous plant large-fruited Chinese hawthorn Crataegus pinnatifida Bge.var.major N.E.Br.
Or the dry mature fruit of hawthorn Crataegus pinnatifida Bge..It is sour, sweet, tepor.Returns spleen, stomach, Liver Channel.It helps digestion
Stomach invigorating, scattered stasis change turbid lipid-loweringing.For meat stagnation, gastral cavilty turgor, diarrhea dysentery abdominal pain, blood stasis closed, postpartum stasis, trusted subordinate
Shouting pain, chest impediment and cardialgia, hernia pain, hyperlipidemia.
(2) lotus leaf is the dried leaf of nymphaeaceae plant lotus Nelumbo nucifera Gaertn..Hardship is put down.Return liver, spleen,
Stomach meridian.Clearing away summer-heat and eliminating dampness, sending up the lucid yang, cooling blood and hemostasis.For hot summer weather polydipsia, summer heat damp diarrhea, splenasthenic diarrhea, blood-head tells nosebleed, hematochezia
Metrorrhagia and metrostaxis.
(3) pueraria lobata is the dry root of plants of the genus elegant jessamine Pueraria lobate (Willd.) Ohwi.It is sweet, pungent,
It is cool.Returns spleen, stomach, lung channel.Expelling pathogenic factors from muscles and skin is brought down a fever, and is promoted the production of body fluid to quench thirst, promoting eruption, Shengyang Zhixie, clearing and activating the channels and collaterals, relieving alcoholism.
(4) green tea, chemical component mainly include polyphenol, caffeine and amino acid, catechin rich in green tea,
Middle tea polyphenols are the most abundant.Green tea and polyphenol therein are played a positive role in terms for the treatment of a variety of diseases, such as cancer, glycosuria
Disease, cardiovascular disease, obesity etc..
(5) fructus lycii is the dry mature fruit of Lycium barbarum L. of solanaceae Lycium barbarum L..Sweet and neutral.Return
Liver and kidney channel.Chinese medicine fructus lycii is listed as top grade first recorded in Shennong's Herbal, and long term usage heavily fortified point muscles and bones cures mainly kidney deficiency and liver, essence and blood
Deficient, tinnitus and people's spermatorrhea.
(6) Poria cocos is the dry sclerotia of polyporaceae fungus Poria cocos (Schw.) Wolf.It is sweet, light, it puts down.
Return heart, lung, spleen, kidney channel.Clearing damp and promoting diuresis, invigorating the spleen calming heart.For edema and little urine, phlegm retention anti-dazzle nervous, spleen eating less, loose stool diarrhea, the heart
It is refreshing uneasy, insomnia of palpitating with fear, clearing damp and promoting diuresis, strengthening the spleen and reducing phlegm, antitoxic heart-soothing and sedative；Tonifying spleen, transporting nutriment enter blood, and deficiency of enriching blood helps
Digestion；Transformation of body flaud eliminates the heresy of phlegm wet, mild-natured fever and chills.
(7) sea-buckthorn is the dry mature fruit of Elaeangnaceae plant sea-buckthorn Hippophae thamnoides L..Acid,
It is puckery, temperature.Returns spleen, stomach, lung, the heart channel of Hang-Shaoyin.Reinforcing spleen to promote digestion, cough-relieving apophlegmatic, promoting blood circulation to remove blood stasis.For spleen eating less, dyspeptic abdominalgia, phlegm of coughing
It is more, chest impediment and cardialgia, blood stasis closed, flutter stasis of blood arsine.
(8) celery powder, containing a variety of active ingredients, such as flavone compound, volatile oil, unsaturated fatty acid, terpene, perfume (or spice)
Beans chlorins compound etc..Dietary fiber and flavone compound in celery play an important role during lipid-loweringing.
(9) mulberry leaf are the dried leaf of moraceae plants mulberry Morus alba L..It is sweet, bitter, it trembles with fear.Return lung, Liver Channel.Evacuate wind
Heat, clearing away the lungheat and moisturizing are clear liver and improved vision.For anemopyretic cold, lung-heat type cough, dizziness headache, red eyes and dim-sighted.
(10) konjaku powder also contains konjac polysaccharide, and have containing the mineral matter elements such as multivitamin and potassium, phosphorus, selenium
There is the characteristics of low in calories, low fat and high-cellulose.Activating microcirculation and removing stasis medicinal, relax bowel and defecation, reduction are to fatty absorption, weight-reducing of allaying one's hunger.
(11) pawpaw is that the drying of rosaceous plant chaenomeles lagenaria Chaenomeles speciosa (Sweet) Nakai is close
Ripening fruits.Acid, temperature.Return liver, the spleen channel.Relaxing tendons and activating collaterals, stomach function regulating dampness elimination.For arthritis with fixed pain caused by dampness muscular constricture, waist and knee joints acid weight pain, summer-heat and damp
It vomits and diarrhoea, spasm contraction pain, tinea pedis oedema.
(12) rhizoma polygonati is liliaceous plant polygonatum kingianurn Polygonatum kingianum Coll.et Hemsl, rhizoma polygonati
The dry rhizome of Polygonatum sibiricum Red. or polygonatum cyrtonema Polygonatum cyrtonema Hua.It is sweet,
It is flat.With tonifying middle-Jiao and Qi, moistening herat and lung, tonifying kidney and benefiting sperm, strengthening the bones and muscles, five viscera settling, only fever and chills, replenishing essence marrow and other effects.
The natural plant raw material of above-mentioned 12 kinds of integration of drinking and medicinal herbs acts synergistically, and can play auxiliary reducing blood lipid, weight-reducing, protection liver
Effect that is dirty, improving intestinal flora.It obtains medical treatment height according to traditional Chinese medicine theory and Chinese medicine system pharmacology big data analysis
Pionemia and fat prescription, and verified by the means of modern biochemistry, prescription proportion rationally, has highly significant
Effect.According to Traditional Chinese medical theory, hyperlipidemia and fat this void (spleen deficiency loses fortune) that belongs to mark real (phlegm heat, the stasis of blood are stagnant) mixture of asthenia and sthenia
Card, it is dirty to be related to him in spleen site of pathological change.The present invention is using hawthorn, lotus leaf, pueraria lobata and green tea as main ingredient, by righting (tonifying Qi),
It improves based on temper, reuses qi-regulating, activating microcirculation and removing stasis medicinal, clearing heat and promoting diuresis (phlegm) class lipid-lowering medicine to control its mark.The present invention is with hawthorn, lotus
Leaf, pueraria lobata, green tea are main ingredient, help fortune (hawthorn, sea-buckthorn), kidney-nourishing (fructus lycii, rhizoma polygonati) method with Zhi Qiben with invigorating the spleen；With dispelling
Phlegm wet (lotus leaf, pawpaw, Poria cocos), removes food retention (hawthorn, sea-buckthorn) method to control its mark at heat-clearing malicious (lotus leaf, pueraria lobata, green tea, mulberry leaf)；
It is aided with celery and the konjaku powder relax bowel and defecation of high dietary-fiber simultaneously.
The present invention is using 12 kinds of drug cooperations such as hawthorn, lotus leaf, pueraria lobata, green tea, and there is no by this 12 kinds in the prior art
Medicine material combination is used for reducing blood lipid, and it is understood that the compatibility effect between different Chinese medicine materials is different, the monarch and his subjects
Assistant makes, i.e., in the identical situation of monarch drug in a prescription, selects different ministerial drugs, compatibility effect is different, and the effect of finally obtained drug can
Can be multifarious, same ministerial drug is identical, and in the case that monarch drug in a prescription is different, the effect of final drug also has difference, in some instances it may even be possible to
The type for treating disease is also different.Therefore, although above-mentioned part material is disclosed in different documents in reducing blood lipid, weight-reducing
The application of aspect, but the compatibility effect of a combination thereof together can not be envisioned, the effect of final drug be it is difficult to predict.
Hawthorn, lotus leaf, pueraria lobata, green tea are monarch in prescription of the present invention, and function is to improve temper, phlegm reduction of blood circulation promoting；With fructus lycii, Poria cocos, sea-buckthorn,
Rhizoma polygonati is minister, there is the benefits of QI invigorating promoting flow of qi and blood circulation, dampness removing resolving sputum, further enhances the function of monarch drug in a prescription qi-regulating, phlegm reduction of blood circulation promoting, mulberry leaf, wood
Melon is that assistant is allowed to product.The more qi-regulatings of the recipe, activating microcirculation and removing stasis medicinal, dampness removing resolving sputum are made a general survey of, and gives the medicines such as QI invigorating promoting the circulation of qi, clearing liver, dampness removing both
The benefits of phlegm reduction of blood circulation promoting can be consolidated, but Each performs its own functions achievees the purpose that the secondary illness for the treatment of, it is mutual for hyperlipidemia and fat phlegm-blood stasis
Card person is tied, is to shoot the arrow at the target, guides drugs to illness station.Not only principal and subordinate is orderly for full side's monarch, but also Each performs its own functions, can guide drugs to illness station,
It also makes overall plans, disappears turbid good recipe for phlegm reduction of blood circulation promoting, promoting the circulation of qi.It is matched, the reducing blood lipid of obtained functional food composite,
Weight-reducing, improves intestinal flora significant effect at liver protection, achieves unexpected technical effect.
Compared with prior art, the beneficial effects of the present invention are:
(1) food compositions with auxiliary reducing blood lipid, hepatoprotective effect of losing weight provided by the invention, in each group divided dose model
Enclosing interior can significantly reduce hyperlipidemia model rat body weight, rouge/body ratio, food utilization and blood triglyceride, total cholesterol and low
Density lipoprotein-cholesterol is horizontal；Also hyperlipidemia model rat liver index and glutamic-pyruvic transaminase, alkaline phosphatase levels can be reduced；
And it is remarkably improved Bacteroidetes relative abundance, and reduce Firmicutes relative abundance, there is specific auxiliary reducing blood lipid, weight-reducing
And the effect of improving intestinal flora.
(2) present invention combines traditional traditional Chinese medical theory and Chinese medicine system pharmacology big data analysis to obtain auxiliary reducing blood lipid
Prescription, and verified by the means of modern biochemistry, have the function of highly significant.Safety is without side-effects, is suitble to
It takes for a long time.
(3) food compositions with auxiliary reducing blood lipid, liver protection of losing weight of the invention, compatibility is reasonable, simple and easy, is
Integration of drinking and medicinal herbs composition, safety is without side-effects, is suitble to take for a long time.
Detailed description of the invention
Fig. 1 is that prescription 1~3 influences hyperlipidemia model rat TG and TC.
Fig. 2 be of the invention 4 taste main ingredient hawthorn, lotus leaf, pueraria lobata, green tea ingredient-target spot network.Wherein generation inside figure
Table chemical component, periphery represent target spot, and periphery black hexagon represents target spot relevant to hyperlipidemia.
Fig. 3 is enriched to for 4 taste main ingredient hawthorn of the invention, lotus leaf, pueraria lobata, green tea according to ingredient, target spot and hyperlipidemia
15 advanced bubble diagram before relevant bioprocess or access ranking.
Fig. 4 is influence of the present invention to the weight gain of hyperlipidemia model rat body weight, food ration, food utilization and rouge body ratio.
Fig. 5 is that hyperlipidemia model rat fat four influences, (A-D is respectively TG, TC, LDL-C and HDL-C water to the present invention
It is flat).
Fig. 6 is influence of the present invention to rat liver Fatty synthesis mrna expression.
Fig. 7 is influence of the present invention to rat liver index.
Fig. 8 is that rat liver function six influences, (A-F is respectively glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminease to the present invention
(AST), glutamyl transpeptidase (γ-GT), alkaline phosphatase (ALP), total protein (TP) and albumin (ALB) are horizontal).
Fig. 9 is that (A-D is respectively Firmicutes (Firmicutes) abundance, bacteroid for influence of the present invention to intestinal flora
Door (Bacteroidetes) abundance, the horizontal thermal map of Proteobacteria (Proteobacteria) abundance and section).
Figure 10 is that the side of tearing open 1~3 influences hyperlipidemia model rat TG and TC.
In above each figure:#P < 0.05,##P < 0.01,###P < 0.001, compared to the blank group；*P < 0.05,**P < 0.01,***P
< 0.01, compared with model group (n=10).
Specific embodiment
Form by the following examples is described in further detail above content of the invention again, but should not be by this
The range for being interpreted as the above-mentioned theme of the present invention is only limitted to example below, and all technologies realized based on above content of the present invention are equal
Belong to the scope of the present invention.
Embodiment 1: optimal prescription screening experiment
Prescription 1: it is a kind of with the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight, by following raw material weight number
Group be grouped as: 10 parts of hawthorn, 30 parts of lotus leaf, 5 parts of pueraria lobata, 5 parts of green tea, 5 parts of fructus lycii, 3 parts of Poria cocos, 2 parts of sea-buckthorn, celery powder
4 parts, 3 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati.
Prescription 2: it is a kind of with the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight, by following raw material weight number
Group be grouped as: 25 parts of hawthorn, 15 parts of lotus leaf, 10 parts of pueraria lobata, 6 parts of green tea, 3 parts of fructus lycii, 3 parts of Poria cocos, 2 parts of sea-buckthorn, celery
1 part of powder, 3 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati.
Prescription 3 (optimal prescription): it is a kind of with the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight, by following original
The group of material parts by weight is grouped as: 20 parts of hawthorn, 20 parts of lotus leaf, 10 parts of pueraria lobata, 10 parts of green tea, 5 parts of fructus lycii, 3 parts of Poria cocos, sand
2 parts of spine, 4 parts of celery powder, 2 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati.
The composition the preparation method comprises the following steps: weigh appropriate each raw material respectively, clean, purify, dry, crush, cross 120
Mesh can be used for testing after mixing powder.
Experimental method:
[animal packet and administration]
It chooses healthy adult animal 90 (SPF rank male rat, 180 ± 20g), it is common that feed is maintained to adapt to raising 7
It, randomly selects 10 respectively as blank group.80 are only given hyperlipidemia model feed (10% sucrose, 12% lard, 10% egg
Huang, 1% cholesterol, 0.5% sodium taurocholate, 66.5% basal feed) it is grouped after 1 week, according to prescription 1-3 configuration suspension (by big
The raw medicinal herbs of the meterings such as the every kg of mouse weight is administered, dosage 1.26g/kg), experimental animal is grouped into model by weight at random
Group, 1 group of prescription, 2 groups of prescription, 3 groups of prescription, every group 10.Same volume solvent is given in blank control group, model group stomach-filling, that is, steams
Distilled water；Corresponding prescription 1~3 is given in stomach-filling to remaining each group respectively.Blank control group continues to give maintenance feed, model control group and
Each medicine group continues to give hyperlipidemia model feed, weighs weight weekly, and adjust given low by new weight, is administered 42 days.Respectively
Group rat free water is ingested.
[experimental procedure]
Dorsal position fixes groups of animals, extracting vein blood, and 1500r/min is centrifuged 15min, separates serum, full automatic biochemical apparatus
Measure blood lipid level (TG and TC) respectively.
[data analysis]
All experimental datas indicate that data are carried out using 16.0 statistics analysis software package of SPSS with average ± standard deviation
Statistical procedures, comparison among groups use one-way analysis of variance, compare two-by-two using Turkey HSD post hoc test method
Carry out statistical analysis.Specification test level is α=0.05, and the no significant difference of P>0.05, the difference of P<0.05 is with conspicuousness.
[experimental result]
Compared with blank control group, model group serum TG and the horizontal significant raising of TC (P < 0.001 is shown in Table 1, Fig. 1).Prescription
1~3 to reduce serum TG and TC to some extent horizontal (P < 0.05 is shown in Table 1, Fig. 1), and wherein 3 effect for reducing blood fat of prescription is the most
Obviously, therefore prescription 3 is chosen as optimal prescription, be used for later period pharmacodynamic experiment.
The different prescriptions of table 1 to hyperlipidemia model rat fat influence (mmol/L,N=10)
| Group | TG | TC |
| Blank group | 0.42±0.09 | 1.75±0.25 |
| Model group | 1.48±0.22### | 3.02±0.35### |
| Prescription 1 | 0.90±0.15* | 2.33±0.18* |
| Prescription 2 | 0.73±0.20** | 2.12±0.11** |
| Prescription 3 | 0.62±0.15** | 2.03±0.40** |
Note: compared with blank control group,#P < 0.05,##P < 0.01,###P<0.001；Compared with model group, * P < 0.05, * *
P<0.01
Embodiment 2: prescription is carried out by literature search and using network pharmacology big data analysis
[experimental principle and method]
Network pharmacology is the new disciplines developed on the basis of systems biology, protein science, genomics, based on pair
The understanding of " drug-target-gene-disease phenotype " interactive network, does disease by the analysis and observation drug of network
Pre- and influence, is more nearly the actual conditions of drug development and disease, improves the success rate of drug development.Chinese medicine is one and contains
There is the complex system of abundant ingredient, application network pharmacology and bioinformatics study Chinese medicine system, analyzing molecules-point
Son, molecule-target, the interaction between target-disease, to the sieve of the ingredient of 4 taste main ingredient materials, target spot in the present composition
Choosing, enrichment analysis, filter out target spot relevant to hyperlipidemia occurrence and development and gene, are the exploitation of the present composition and excellent
Change provides theory support.
TCMSP database (http://sm.nwsuaf.edu.cn/lsp/tcmsp.php)；
TCMID database (http://www.megabionet.org/tcmid/)；
TCM Database@Taiwan database (http://tcm.cmu.edu.tw/)；
TTD database (http://bidd.nus.edu.sg/group/TTD/ttd.asp)；
Uniprot database (http://www.uniprot.org/)；
DAVID database (https: //david.ncifcrf.gov/summary.jsp).
[experimental result]
4 taste main ingredient materials of the invention filter out 178 potential activity ingredients, 352 target spots altogether, wherein be enriched to
The relevant target spot of hyperlipidemia is 90 total, accounts for 1/4 or more of screening target spot, sees Fig. 2.In bubble diagram before ranking 15 access
It is all closely bound up with glucose-lipid metabolism process, from the angle of big data bioinformatic analysis, absolutely prove the conjunction of prescription of the present invention
Rationality and potentiality with auxiliary lipid-lowering function, as shown in Table 2 and Fig. 3.
In 2 bubble diagram of table with glycolipid metabolism related biological processes or access clause name
| Term | GO-BP or Pathway title | P value |
| Inflammatory response | Inflammatory reaction | 3.24E-09 |
| Regulation of lipolysis in adipocytes | Adjust the lipolysis of fat cell | 2.22E-06 |
| Insulin resistance | Insulin resistance | 2.37E-06 |
| Insulin signaling pathway | Insulin signaling pathway | 1.78E-05 |
| Oxidation-reduction process | Oxidation-reduction process | 2.53E-05 |
| cAMP signaling pathway | CAMP signal path | 5.47E-05 |
| Lipid metabolic process | Regulating Lipid Metabolism | 1.11E-04 |
| Non-alcoholic fatty liver disease(NAFLD) | Non-alcohol fatty liver | 2.32E-04 |
| Sphingolipid signaling pathway | Sphingolipid signal path | 0.0020 |
| Fatty acid biosynthetic process | Fatty acid biological synthesis process | 0.0020 |
| Glucose metabolic process | Glucose metabolic process | 0.0041 |
| Brown fat cell differentiation | Brown fat cell differentiation | 0.010 |
| AMPK signaling pathway | AMPK signal path | 0.010 |
| Positive regulation of fat cell differentiation | The positive regulator of Adipocyte Differentiation | 0.021 |
| PPAR signaling pathway | PPAR signal path | 0.037 |
Embodiment 3: optimal prescription assists the pharmacodynamic evaluation of reducing blood lipid, antiobesity action
Select the optimal prescription that filters out in embodiment 1 to carry out pharmacodynamic evaluation, with confirm its assist reducing blood lipid, weight-reducing,
The effect of liver protection and improvement intestinal flora.
Optimal prescription: it is a kind of to assist reducing blood lipid, weight-reducing, liver protection and the multifunctional food composition for improving intestinal flora, by
The group of following raw material weight number is grouped as: 20 parts of hawthorn, 20 parts of lotus leaf, 10 parts of pueraria lobata, 10 parts of green tea, 5 parts of fructus lycii, Poria cocos
3 parts, 2 parts of sea-buckthorn, 4 parts of celery powder, 2 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati.
The composition the preparation method comprises the following steps: weigh appropriate each raw material respectively, clean, purify, dry, crush, cross 120
Mesh can be used for testing after mixing powder.
[animal packet and administration]
It chooses healthy adult animal 70 (SPF rank male rat, 180 ± 20g), it is common that feed is maintained to adapt to raising 7
It, randomly selects 20 respectively as blank group, normal high agent group (i.e. high dose is given in not modeling), and every group 10.50 are given
Giving hyperlipidemia model feed, (10% sucrose, 12% lard, 10% yolk, 1% cholesterol, 0.5% sodium taurocholate, 66.5% basis are raised
Material) it is grouped after 1 week, basic, normal, high three kinds of suspensions are configured to (by every kg of rat body weight etc. according to optimal prescription (i.e. prescription 3)
The raw medicinal herbs of metering is administered, and dosage is respectively 0.42g/kg, 0.84g/kg and 1.26g/kg), experimental animal by weight with
Machine is grouped into model group, low dose group, middle dose group, high dose group, positive controls (Simvastatin, dosage 10mg/
Kg rat body weight), every group 10.Same volume solvent, i.e. distilled water are given in blank control group, model group stomach-filling；Remaining each group fills
Stomach gives various dose composite formula and positive control drug.Blank control group continues to give maintenance feed, model control group and
Each medicine group continues to give hyperlipidemia model feed, weighs weight weekly, and adjust given low by new weight, is administered 42 days.Respectively
Group rat free water is ingested.Food ration is recorded weekly, is weighed in 1 time.
[experimental procedure]
1, measurement groups of animals weight gain, food ration weekly, calculate food utilization=weight gain/food ration ×
100%.
2, the fixed rat of dorsal position, extracting vein blood, 1500r/min are centrifuged 15min, separate serum, full automatic biochemical apparatus point
It Ce Ding not four items of blood lipid tests (TG, TC, HDL-C, LDL-C).
3, each group rat perinephric fat, testis peripheral adipose pad are taken respectively, and is weighed, and rouge/body ratio is calculated.
4, rat liver tissue is taken, mRNA in tissue is extracted with Trizol, progress reverse transcription is cDNA, and using it as mould
Plate, carries out cDNA amplification, and real time fluorescent quantitative measures fat synthesis related gene FAS, SREBP-1, PPAR- in liver organization
The mRNA expression of γ.
[data analysis]
With embodiment 1.
[experimental result]
1, optimal prescription is to the influence of the weight gain of hyperlipidemia model rat body weight, food ration, food utilization and rouge/body ratio
Each group rat food ration has no marked difference (P > 0.05, Fig. 4 B), prompts the food intake dose of groups of animals consistent,
Without promotion appetite effect.And compared with blank control group, high fat diet model group rats weight gain, rouge/body ratio and food benefit
(P < 0.05, Fig. 4 A, C, D) is dramatically increased with rate.Compared with model group, high fat diet is can be significantly reduced in high, middle dose group
Rat body weight weight gain, rouge body ratio and food utilization (P < 0.05, Fig. 4 A, C, D).Prompt optimal prescription height, middle dose group that can subtract
Few lipopexia, has antiobesity action, is shown in Table shown in 3, Fig. 4.
3 each dosage group of optimal prescription of table is to the weight gain of hyperlipidemia model rat body weight, food ration, food utilization and rouge body ratio
Influence (N=10)
| Group | Weight gain (g) | Food ration (g/ days) | Food utilization (%) | Rouge/body ratio (%) |
| Blank group | 107.0±11.4 | 25.7±1.9 | 4.16±0.44 | 3.11±0.21 |
| Normally+high dose group | 98.2±17.6 | 22.4±1.2 | 4.38±0.79 | 3.02±0.23 |
| Model group | 152.2±9.0# | 21.5±3.1 | 7.12±0.48## | 3.96±0.28## |
| Low dose group | 133.5±20.8 | 20.1±2.9 | 6.64±1.08 | 3.80±0.35 |
| Middle dose group | 115.7±10.2* | 21.3±2.9 | 5.43±0.80* | 3.34±0.31* |
| High dose group | 113.9±17.8* | 20.3±3.2 | 5.61±0.88* | 3.27±0.24* |
| Positive controls | 112.4±21.7* | 20.7±2.7 | 5.42±0.94* | 3.20±0.09* |
Note: compared with blank control group,#P < 0.05,##P < 0.01,###P<0.001；Compared with model group, * P < 0.05, * *
P<0.01
2, influence of the optimal prescription to hyperlipidemia model rat fat four
Compared with blank control group, high fat diet model group rats serum triglyceride (TG), total cholesterol (TC) and low
Density lipoprotein-cholesterol (LDL-C) significantly increases (P < 0.001), prompts modeling success.Compared with model group, middle and high dose
Amount group and positive controls can significantly reduce serum TC, TG and LDL-C level (P < 0.05), effect and positive control drug phase
When each administration group serum High Density Lipoprotein Cholesterol (HDL-C) slightly has raising trend compared with model control group, without significant statistics
Difference (P > 0.05).The optimal prescription of the prompt present invention is high, middle dose group has auxiliary effect for reducing blood fat.Meanwhile optimal prescription is high
Dosage group does not have effect for reducing blood fat to intact animal, is shown in Table 4, Fig. 5.
4 each dosage group of optimal prescription of table to hyperlipidemia model rat fat influence (mmol/L,N=10)
| Group | TG | TC | LDL-C | HDL-C |
| Blank group | 0.58±0.17 | 1.87±0.18 | 0.49±0.13 | 1.17±0.25 |
| Normally+high dose group | 0.48±0.15 | 1.96±0.18 | 0.57±0.10 | 1.19±0.08 |
| Model group | 1.15±0.27### | 2.92±0.40### | 1.08±0.19### | 1.35±0.14 |
| Low dose group | 0.95±0.25 | 2.55±0.35 | 0.97±0.12 | 1.56±0.16 |
| Middle dose group | 0.77±0.20* | 2.26±0.19** | 0.80±0.09 | 1.32±0.17 |
| High dose group | 0.67±0.16** | 2.16±0.16** | 0.75±0.07* | 1.40±0.15 |
| Positive controls | 0.66±0.21** | 2.36±0.29** | 0.75±0.14* | 1.37±0.21 |
Note: compared with blank control group,#P < 0.05,##P < 0.01,###P<0.001；Compared with model group, * P < 0.05, * *
P<0.01
3, influence of the optimal prescription to hyperlipidemia model rat liver fat synthesis related gene expression
Compared to the blank group, model group liver fat acid enzyme (FAS), Sterol regulatory element binding protein -1
(SREBP-1) and the mRNA expression of peroxisome proliferator-activated receptors-γ (PPAR- γ) significantly increase (P <
0.01).And compared with model group, high dose group can significantly reduce Induced by High Fat Diet in Rats liver F AS, SREBP-1 and PPAR- γ's
MRNA expression (P < 0.05) prompts the present invention can be by inhibiting Fatty synthesis gene expression to reduce Fat Accumulation and blood lipid
Level has the function of pre- preventing obesity and auxiliary reducing blood lipid, as shown in Figure 6.
Embodiment 4: protective effect of the optimal prescription to liver
[animal packet and administration]
With embodiment 3.
[experimental procedure]
1, the fixed rat of dorsal position, extracting vein blood, 1500r/min are centrifuged 15min, separate serum, full automatic biochemical apparatus point
It Ce Ding not liver function six (ALT, AST, γ-GT, ALP, TP, ALB).
2, it sufficiently exposes and removes taking-up liver, weigh and record, calculating organ index=organ weights/weight ×
100%.
[data analysis]
With embodiment 1.
[experimental result]
1, influence of the optimal prescription to hyperlipidemia model rat liver index
Compared with blank control group, model group liver index is significantly increased (P < 0.01), prompts high fat diet induction may
Make Liver fatty deposition.And only optimal prescription high dose group can be significantly reduced high fat diet induced rat liver index (P <
0.05), and positive controls do not make significant difference (P > 0.05) to liver index, see Fig. 7.
2, influence of the optimal prescription to hyperlipidemia model rat liver function six
Compared with blank control group, model group rats serum glutamic pyruvic transminase (ALT) and alkaline phosphatase (ALP) content are aobvious
Work increases (P < 0.05), prompts high fat diet that liver metabolism may be made abnormal.And compared with model group, optimal prescription height, middle dose
Amount group can reduce serum glutamic pyruvic transminase (ALT) and alkaline phosphatase (ALP) content to some extent, and positive controls are then
Without significant difference (P > 0.05).Meanwhile glutamic-oxalacetic transaminease (AST), glutamyl transpeptidase (γ-GT), total protein (TP) and white egg
No significant difference (P > 0.05) between white (ALB) content each group.In conjunction with liver index and liver function indexes, prompt optimal prescription it is high, in
Dosage group can promote Liver Lipid Metabolism, reduce fat deposition, has liver protection effect, sees Fig. 8, table 5.
The optimal prescription of table 5 to hyperlipidemia model rat liver function six influences (U/L,N=10)
Note: compared with blank control group,#P < 0.05,##P < 0.01,###P<0.001；Compared with model group, * P < 0.05, * *
P<0.01
Embodiment 5: adjustment effect of the optimal prescription to High fat diet rats intestinal flora
[animal packet and administration]
With embodiment 3.
[experimental procedure]
Fresh excreta in each group Rat-rectum is taken, intestinal flora detection is carried out.Use Qubit 2.0Fluorometer
(Invitrogen, Carlsbad, CA) detects the concentration of DNA sample, uses MetaVxTMLibrary construction Kit, sequencing text
Library.Using 30-50ng DNA as template, using design a series of PCR primers amplification prokaryotes 16S rDNA on include V3 and
2 hypervariable regions of V4.Using 2100 biological analyser of Agilent (Agilent Technologies, Palo Alto,
CA, USA) detection Library Quality, and detected by Qubit2.0 Fluorometer (Invitrogen, Carlsbad, CA)
Library concentration.Interpretation of result simultaneously draws thermal map.
[data analysis]
With embodiment 1.
[experimental result]
Species abundance difference results show (as shown in Fig. 9 A~C), 1) on door horizontal bedding, and with blank control group phase
Than Firmicutes (Firmicutes) abundance dramatically increases (P < 0.05) in the excrement of high fat diet model group rats, and quasi- bar
Bacterium door (Bacteroidetes) abundance significantly reduces (P < 0.05), and conditioned pathogen Proteobacteria (Proteobacteria) is rich
Degree is significant to increase (P < 0.05), prompts high fat diet to will lead to Firmicutes bacterial number in enteric microorganism and increases, bacteroid
Door bacterial number is reduced, to influence weight and body fat level.And optimal prescription middle dose group can make Firmicutes, deformation respectively
Bacterium door abundance reduces (P < 0.05), while being that Bacteroidetes abundance increases (P < 0.05), to be sent out by adjusting intestinal flora
Wave the effect for adjusting rouge loss of weight.2) (see Fig. 9 D) on section's horizontal bedding, compared with blank control group, high fat diet model group rats
Species abundance it is obviously abnormal, a variety of flora Abundance Anomalies increase, and individual flora Abundance Anomalies reduce, and the present invention can make object
Kind composition ratio restores to close normal horizontal.Therefore, the intestinal microflora of the adjustable high fat diet induction of the present invention
Variation.
Embodiment 6: the safety evaluatio of optimal prescription
[animal packet and administration]
It chooses healthy adult animal 40 (SPF rank rat, half male and half female, 180 ± 20g), it is common that feed is maintained to adapt to
Raising 7 days, is randomly divided into blank group and optimal prescription group, and every group 20 (half male and half female).According to optimal prescription (i.e. prescription 3)
Be configured to suspension (by the meterings such as the every kg of rat body weight raw medicinal herbs be administered, dosage is respectively 1.26g/kg) stomach-filling to
Same volume solvent, i.e. distilled water are given in medicine, blank control group stomach-filling.Weight is weighed weekly, and adjusts given low by new weight,
Administration 90 days.Each group rat free water is ingested.Food ration is recorded weekly, is weighed in 1 time.
[experimental procedure]
1, groups of animals weight, food ration and food utilization weekly are measured.
2, general behavior, performance, poisoning symptom and death state.
3, each internal organs Histopathology detection.
[experimental result]
During this test, rat behavior expression without exception, hair is normal, no death condition.Successive administration 90 days, greatly
Mouse is without apparent toxic reaction and death.Compared with blank control group, the rat of optimal prescription group weight, food ration and food weekly
Object utilization rate is without significant difference；Organ is normal in rat splanchnocoel, and no obvious lesion occurs；During each organ has no under the microscope
Toxic pathology changes.Therefore, the present invention is without side-effects safely, is suitble to take for a long time.
Embodiment 7: the optimal prescription side of tearing open comparative analysis
In order to further verify the reasonability and optimal efficiency of optimal prescription, respectively with regard to four kinds of main ingredient ingredients in optimal prescription into
It has gone ingredient replacement, comparison side 1~4 has been respectively obtained, for the comparison (as follows) with optimal prescription effect.
Optimal prescription: it is a kind of to assist reducing blood lipid, weight-reducing, liver protection and the multifunctional food composition for improving intestinal flora, by
The group of following raw material weight number is grouped as: 20 parts of hawthorn, 20 parts of lotus leaf, 10 parts of pueraria lobata, 10 parts of green tea, 5 parts of fructus lycii, Poria cocos
3 parts, 2 parts of sea-buckthorn, 4 parts of celery powder, 2 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati.
The side of comparison 1: it is a kind of auxiliary reducing blood lipid, weight-reducing, liver protection and improve intestinal flora multifunctional food composition, by with
The group of lower raw material weight number is grouped as: 20 parts of radix polygonati officinalis, 20 parts of lotus leaf, 10 parts of pueraria lobata, 10 parts of green tea, 5 parts of fructus lycii, Poria cocos 3
Part, 2 parts of sea-buckthorn, 4 parts of celery powder, 3 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati, the preparation method is the same as that of Example 1.
The side of comparison 2: it is a kind of auxiliary reducing blood lipid, weight-reducing, liver protection and improve intestinal flora multifunctional food composition, by with
The group of lower raw material weight number is grouped as: 20 parts of hawthorn, 20 parts of Radix Glycyrrhizae, 10 parts of pueraria lobata, 10 parts of green tea, 5 parts of fructus lycii, Poria cocos 3
Part, 2 parts of sea-buckthorn, 4 parts of celery powder, 3 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati, the preparation method is the same as that of Example 1.
The side of comparison 3: it is a kind of auxiliary reducing blood lipid, weight-reducing, liver protection and improve intestinal flora multifunctional food composition, by with
The group of lower raw material weight number is grouped as: 20 parts of hawthorn, 20 parts of lotus leaf, 10 parts of the root of Dahurain angelica, 10 parts of green tea, 5 parts of fructus lycii, Poria cocos 3
Part, 2 parts of sea-buckthorn, 4 parts of celery powder, 3 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati, the preparation method is the same as that of Example 1.
The side of comparison 4: it is a kind of auxiliary reducing blood lipid, weight-reducing, liver protection and improve intestinal flora multifunctional food composition, by with
The group of lower raw material weight number is grouped as: 20 parts of hawthorn, 20 parts of lotus leaf, 10 parts of pueraria lobata, 10 parts of semen coicis, 5 parts of fructus lycii, Poria cocos
3 parts, 2 parts of sea-buckthorn, 4 parts of celery powder, 3 parts of mulberry leaf, 1 part of konjaku powder, 1 part of pawpaw, 1 part of rhizoma polygonati, the preparation method is the same as that of Example 1.
The composition the preparation method comprises the following steps: weigh appropriate each raw material respectively, clean, purify, dry, crush, cross 120
Mesh can be used for testing after mixing powder.
Experimental method:
[animal packet and administration]
With embodiment 1.
[experimental procedure]
With embodiment 1.
[data analysis]
With embodiment 1.
[experimental result]
Model group serum TG and TC level are significantly higher than blank control group (P < 0.001 is shown in Table 6, Figure 10), and only optimal place
It is horizontal (P < 0.001 is shown in Table 6, Figure 10) that Fang Zuke significantly reduces model group TG and TC, and comparison side 1~4 does not significantly reduce mould
The TG and TC of type rat are horizontal (P > 0.05).Meanwhile compared with optimal prescription group, there is significant statistics with it in comparison side 1~4
It learns difference (P < 0.05), significant effect cannot be played by prompting to replace any ingredient of main ingredient in optimal prescription, optimal prescription
Medicinal material proportion is optimal proportion, has effects that the uniqueness and importance played.
Comparative analysis that the different prescriptions of table 6 influence hyperlipidemia model rat fat (mmol/L,N=10)
| Group | TG | TC |
| Blank group | 0.42±0.09 | 1.75±0.25 |
| Model group | 1.48±0.22### | 3.02±0.35### |
| Optimal prescription group | 0.62±0.15** | 2.03±0.40** |
| The side of comparison 1 | 1.35±0.25▲ | 2.85±0.18▲ |
| The side of comparison 2 | 1.25±0.19▲ | 2.76±0.19▲ |
| The side of comparison 3 | 1.23±0.11▲ | 2.54±0.25▲ |
| The side of comparison 4 | 1.30±0.10▲ | 2.50±0.15▲ |
Note: compared with blank control group,#P < 0.05,##P < 0.01,###P<0.001；Compared with model group, * P < 0.05, * *
P<0.01；Compared with optimal prescription group,▲P < 0.05,▲▲P<0.01。
The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention, for the skill of this field
For art personnel, the invention may be variously modified and varied.All within the spirits and principles of the present invention, made any to repair
Change, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (9)
1. a kind of with the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight, which is characterized in that by weight by following components
Part composition: 20~25 parts of hawthorn, 20~25 parts of lotus leaf, 10~16 parts of pueraria lobata, 10~18 parts of green tea, 4~6 parts of fructus lycii, Poria cocos 4
~8 parts, 2~4 parts of sea-buckthorn, 1~3 part of celery powder, 1~3 part of mulberry leaf, 1~2 part of konjaku powder, 1~3 part of pawpaw, rhizoma polygonati 1~2
Part.
2. the preparation method as described in claim 1 with auxiliary reducing blood lipid, the food compositions for hepatoprotective effect of losing weight, special
Sign is, includes the following steps:
(1) 20~25 parts of hawthorn, 20~25 parts of lotus leaf, 10~16 parts of pueraria lobata, 10~18 parts of green tea, Chinese holly are weighed respectively by weight
4~6 parts of matrimony vine, 4~8 parts of Poria cocos, 2~4 parts of sea-buckthorn, 1~3 part of celery powder, 1~3 part of mulberry leaf, 1~2 part of konjaku powder, pawpaw 1
~3 parts, 1~2 part of rhizoma polygonati, clean, purify, dry, crush, and cross 120 meshes, obtain powder；
(2) after mixing above-mentioned powder, above-mentioned 20% mannitol of powder total weight is added, is uniformly mixed, then pelletizes, is dry,
Obtain hybrid particles；
(3) magnesium stearate of its total weight 0.5% is added in hybrid particles, is uniformly mixed, required dosage form is then made.
3. as described in claim 1 there are the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight to drop as preparation auxiliary
Blood lipid weight-reducing, protects liver, improves the purposes in the health food of intestinal flora.
4. as described in claim 1 there are the food compositions for assisting reducing blood lipid, hepatoprotective effect of losing weight to drop as preparation auxiliary
Blood lipid, weight-reducing, the purposes for protecting liver, the drug for improving intestinal flora.
5. purposes as claimed in claim 4, which is characterized in that auxiliary material preparation can be added in the food compositions as needed
At any suitable drug oral preparation.
6. the purposes as described in claim 4-5 is any, which is characterized in that the peroral dosage form of the drug be granule, tablet,
Capsule, bagged instant preparation, effervescent agent, powder, oral solution, pill etc., preferably granule, tablet, capsule and bagged instant preparation.
7. it is as described in claim 1 have auxiliary reducing blood lipid, hepatoprotective effect of losing weight food compositions as functional food
Purposes.
8. being used for the purposes of functional food as claimed in claim 5, which is characterized in that the functional food is beverage or food
Product.
9. the food compositions with auxiliary reducing blood lipid, hepatoprotective effect of losing weight as claimed in claim 7, which is characterized in that institute
Stating auxiliary material is pharmaceutically acceptable auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910419308.2A CN110075216B (en) | 2019-05-20 | 2019-05-20 | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910419308.2A CN110075216B (en) | 2019-05-20 | 2019-05-20 | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110075216A true CN110075216A (en) | 2019-08-02 |
| CN110075216B CN110075216B (en) | 2021-08-31 |
Family
ID=67420892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910419308.2A Active CN110075216B (en) | 2019-05-20 | 2019-05-20 | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110075216B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604773A (en) * | 2019-10-31 | 2019-12-24 | 四川大学华西医院 | Composition for regulating lipid metabolism disorder and preparation method and application thereof |
| CN112971121A (en) * | 2019-12-12 | 2021-06-18 | 辽宁中健医药科技有限公司 | Functional food composition for increasing bone density and regulating intestinal flora and preparation method thereof |
| CN113499377A (en) * | 2021-04-23 | 2021-10-15 | 黑龙江中医药大学 | Composition with auxiliary blood fat reduction and chemical liver injury protection effects and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102085281A (en) * | 2009-12-03 | 2011-06-08 | 李丹 | Medicinal composition having effect of reducing weight |
| CN109091613A (en) * | 2018-10-16 | 2018-12-28 | 安徽明珍堂养生品有限公司 | A kind of concentration tea and preparation method thereof with adjusting blood pressure blood fat effect |
-
2019
- 2019-05-20 CN CN201910419308.2A patent/CN110075216B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102085281A (en) * | 2009-12-03 | 2011-06-08 | 李丹 | Medicinal composition having effect of reducing weight |
| CN109091613A (en) * | 2018-10-16 | 2018-12-28 | 安徽明珍堂养生品有限公司 | A kind of concentration tea and preparation method thereof with adjusting blood pressure blood fat effect |
Non-Patent Citations (1)
| Title |
|---|
| 李向辉: "中药平调方治疗代谢综合征58例", 《中国社区医师(医学专业)》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604773A (en) * | 2019-10-31 | 2019-12-24 | 四川大学华西医院 | Composition for regulating lipid metabolism disorder and preparation method and application thereof |
| CN112971121A (en) * | 2019-12-12 | 2021-06-18 | 辽宁中健医药科技有限公司 | Functional food composition for increasing bone density and regulating intestinal flora and preparation method thereof |
| CN113499377A (en) * | 2021-04-23 | 2021-10-15 | 黑龙江中医药大学 | Composition with auxiliary blood fat reduction and chemical liver injury protection effects and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110075216B (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| CN110075216A (en) | It is a kind of with the food compositions and preparation method thereof, preparation and the application that assist reducing blood lipid, hepatoprotective effect of losing weight | |
| CN115350242B (en) | Glycolipid metabolism regulator and preparation method and application thereof | |
| CN113318201A (en) | Health food for reducing uric acid and preparation method thereof | |
| CN107156590A (en) | Vegetable solid beverage and preparation method thereof | |
| CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
| CN114042126B (en) | Traditional Chinese medicine composition for ascending clear, eliminating turbid, promoting diuresis, benefiting qi, losing weight and reducing fat and preparation method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN102188486B (en) | Pharmaceutical composition for preventing and treating fatty liver and preparation method thereof | |
| CN113975353A (en) | Medicine-food homologous nutrient solution formula for reducing uric acid and treating gout and preparation process thereof | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN106177433A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN111110735A (en) | Lipid-lowering pharmaceutical composition, preparation method and application | |
| CN110575507A (en) | Application of coix seed in regulating intestinal microorganisms | |
| CN101317900B (en) | Chinese medicinal composition for preventing and controlling alcoholic liver damnification and preparation method thereof | |
| CN103750304B (en) | Weight-reducing, fat-reducing and health-protection rhizoma alismatis oral liquid and preparation method thereof | |
| CN102793767B (en) | Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN117180340B (en) | Composition for reducing blood fat and preparation method and application thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |